Influences of saxagliptin on blood glucose spectrum of the patients with type 2 diabetes mellitus
-
摘要: 目的 探讨沙格列汀治疗2型糖尿病患者临床疗效及安全性.方法 将84例2型糖尿病患者随机分为2组,每组42例.2组均给予糖尿病常规治疗,在此基础上,对照组患者继续进行常规西药降糖治疗,研究组患者采用沙格列汀进行治疗.比较治疗前及治疗4、12周后2组患者空腹血糖(FBG)、餐后2h血糖(2hPG)及糖化血红蛋白(HbA1c)水平的变化,并观察体质量指数(BMI)、胰岛素抵抗指数(HOMA-IR)及肝肾功能相关指标的变化及低血糖的发生情况.结果 研究组患者治疗4、12周后FBG、2hPG水平及治疗12周后HbA1c水平均显著低于对照组,差异有统计学意义.治疗4、12周后,研究组患者HOMA-IR较治疗前明显下降,且显著低于对照组.治疗12周后,研究组患者低血糖发生情况明显减少,且显著少于对照组,差异有统计学意义.结论 沙格列汀可有效降低2型糖尿病患者的血糖及HbA1c水平,提高胰岛素抵抗力,减少低血糖的发生,且安全性高.
-
Keywords:
- saxagliptin /
- type 2 diabetes mellitus /
- blood glucose spectrum /
- hypoglycemia
-
-
Cook W, Bryzinski B, Slater J. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors:Results of a pooled analysis of phase 3 clinical trials [J]. {H}Postgraduate Medicine, 2013(3):145. Schwartz S L. Treatment of elderly patients with type 2 diabetes mellitus:a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors [J]. Am J Geriatr Pharmacother, 2010(5):405. 陆菊明. 2型糖尿病治疗新药沙格列汀的药理及临床评价 [J]. {H}中国新药杂志, 2011, (21):2039. Yang W, Lu J, Weng J. Prevalence of diabetes among menand women in China [J]. {H}New England Journal of Medicine, 2010, (12):1090. Hartman I, Rojas E, Rodríguez-Molina D. Incretin-based therapy for type 2 diabetes mellitus:pancreatic and extrapancreatic effects [J]. {H}American Journal of Therapeutics, 2013(4):384. Winkler G. Pleiotropic effects of incretins and antidiabetic drugs with incretine mechanism [J]. {H}Orvosi Hetilap, 2013(7):248. Stefansdottir G, Zoungas S, Chalmers J. Intensive glucose control and risk of cancer in patients with type 2 diabetes [J]. {H}DIABETOLOGIA, 2011(7):1608. McIntosh C H, Demuth H U, Pospisilik J A. Dipeptidyl peptidase Ⅳ inhibitors:how do they work as new antidiabetic agents [J]. {H}Regulatory Peptides, 2005(2):159. Ali S, Fonseca V. Saxagliptin overview:special focus on safety and adverse effects [J]. {H}Expert Opinion Drug Safety, 2013(1):103. Yoshioka K, Isotani H, Ohashi S. Efficacy of vildagliptin on glucose fluctuation in Japanese type 2 diabetic patients with ongoing sulfonylurea based oral glycemic agent therapy [J]. Diabetes Metab Syndr, 2013(1):32.
计量
- 文章访问数: 244
- HTML全文浏览量: 24
- PDF下载量: 6
下载:
苏公网安备 32100302010246号
